Thymosin beta-4 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Thus, while in vitro receptor binding affinities, efficacies, and average concentrations in tissue or plasma are useful, they are not likely to predict DMT concentrations in the vesicles or at synaptic or intracellular receptors. Under these conditions, notions of receptor selectivity are moot, and it seems probable that most of the receptors identified as targets for DMT (see above) participate in producing its psychedelic effects. DMT produces the head-twitch response (HTR), a behavioral proxy of psychedelic-like effects, in rodents. However, its effects in the HTR paradigm in mice that are highly strain-dependent, including producing an HTR comparable to other psychedelics, producing an HTR that is much weaker than that of other psychedelics, or producing no HTR at all. These conflicting results may be due to rapid metabolism of DMT and/or other peculiarities of DMT in different species. Besides the HTR, DMT also substitutes for LSD and DOM in rodent drug discrimination tests. DMT has been found to increase oxytocin levels in humans. It is thought that the rate at which DMT enters the brain, and hence its route of administration, may influence its effects, with more rapid routes like intravenous administration and inhalation potentiating serotonin 5-HT2A receptor activation and consequent hallucinogenic effects. As an example, a bolus intravenous injection of 15 mg DMT produces stronger peak effects than a continuous infusion of 1 mg/minute given over 1.5 hours in spite of the latter achieving higher peak DMT levels.
Lyon, Davor Solter and Azim Surani, for their pioneering work on epigenetic gene regulation in mammalian embryos 2005 Martin Chalfie and Roger Y. Tsien, for their pioneering development of powerful new tools that allow the direct visualization of molecules in living cells 2004 Andrew Z. Fire, Craig C. Mello, Victor Ambros and Gary Ruvkun, for their pioneering achievements in the discovery of gene silencing by double-stranded RNA 2003 Masakazu Konishi, Peter Marler and Fernando Nottebohm, for their pioneering achievements in the ethology and neurology of birdsong 2002 Ira Herskowitz, for his pioneering achievements in yeast genetics and cell biology 2001 Joan A. Steitz, for her work in establishing a sub-field of molecular biology concerning small nuclear ribonucleoproteins 2000 Peter B. Moore, Harry F. Noller, Jr. and Thomas A. Steitz, for their discovery that peptide bond formation on the ribosome is catalyzed exclusively by ribosomal RNA 1999 Roderick MacKinnon, for his research into the molecular foundations of electrical signal generation in neurons and other types of cells 1998 Elizabeth Blackburn and Carol Greider, for their outstanding work on the maintenance of telomeres 1997 H. Robert Horvitz and John E. Sulston, for their pioneering studies of cell lineage in the nematode worm 1996 Richard Axel, Linda B. Buck and A. James Hudspeth, for establishing the molecular basis of the senses of smell and hearing 1995 Thomas D. Pollard and James A. Spudich, for their fundamental contributions to our understanding of molecular motors 1994 Robert G.
Furthermore, the judge stated that the obligation of the public power, especially in health, must always be based in the preservation of the public good, and that it is not agreeable to any possibility that could create risks and turn back from the principle of precaution. The city government appealed the decision and had, by the start of March, again been denied the authorization to distribute the medicine that had already been deemed ineffective and harmful in the public sphere. At the beginning of May, the base allied with Melo in the Municipal Chamber approved a proposal that permitted the free distribution of medication for the supposed treatment of COVID-19 that had been released by the health ministry. The project was seen as a way to attempt to circumvent the court's decision.
== Side effects == The most common side effects of cefadroxil are diarrhea (which, less commonly, may be bloody), nausea, upset stomach, and vomiting. Other side effects include rashes, hives, and itching.
Sources: en.wikipedia.org
== History == Vitacost began operations in 1994 as a catalog retailer of third-party vitamins and supplements under the name Nature's Wealth Company by its founder Wayne Gorsek. In 1999, the company launched Vitacost.com and introduced proprietary vitamins and supplements, which has since expanded to include food, beauty products and sports nutrition. The company completed construction of a manufacturing facility located in Lexington, North Carolina, in 2008. Effective September 1, 2012, Vitacost agreed to lease its manufacturing facilities to a third-party provider. On September 23, 2009, Vitacost went public. Vitacost shares traded on the NASDAQ were suspended on December 7, 2010, for financials not adding up. By the time the stock was reinstated by NASDAQ, the stock had lost most of its value with investors losing almost all of their investment. ("Gebben"). During 2010, the company expanded and upgraded its West Coast distribution facility located in Las Vegas, Nevada. The Company began a similar project for its east coast distribution center, located in Lexington, North Carolina in the spring of 2010, with the building construction completed in the first quarter of 2011. Gorsek was found guilty of securities fraud on January 28, 2003. The SEC Commission announced on this day that the Honorable Jeanne E. Scott, U.S. District Judge for the Central District of Illinois, has found two former brokers and stock promoters, Wayne F. Gorsek ("Gorsek") and Lyndell F.
Despite Hezbollah claiming no attacks against Israel, Israel continued airstrikes across southern Lebanon, the southern suburbs of Beirut and the eastern Beqaa Valley in what was dubbed "Operation Eternal Darkness". In the span of just 10 minutes, 100 airstrikes were launched in Lebanon by Israel during the operation (10 every minute), targeting Hezbollah assets including headquarters, intelligence centers, missile infrastructure, sites related to the Radwan Force and aerial and naval units. Israel stated they had managed to kill Ali Yusuf Harshi, the secretary of Hezbollah's leader at the time. After that, Israel continued fighting. At Iran, authorities claimed for some Israeli violations on their country according to reports. Reports of strikes nearby Tehran and Isfahan were reported. An Israeli drone was allegedly shot down in the vicinity of the city of Lar.
Due to its importance to life, blood is associated with a large number of beliefs. One of the most basic is the use of blood as a symbol for family relationships through birth/parentage; to be "related by blood" is to be related by ancestry or descendence, rather than marriage. This bears closely to bloodlines, and sayings such as "blood is thicker than water" and "bad blood", as well as "Blood brother". Blood is given particular emphasis in the Islamic, Jewish, and Christian religions, because Leviticus 17:11 says "the life of a creature is in the blood." This phrase is part of the Levitical law forbidding the drinking of blood or eating meat with the blood still intact instead of being poured off. Mythic references to blood can sometimes be connected to the life-giving nature of blood, seen in such events as childbirth, as contrasted with the blood of injury or death.
Sources: en.wikipedia.org
=== Board member controversy === Tevanian left Apple on March 31, 2006, and joined the boards of both Dolby Labs and Theranos, Inc. He resigned from the board of Theranos in late 2007, with an acrimonious ending as he faced legal threats and was forced to waive his right to buy a company co-founder's shares, actions he believed were in retaliation for the scepticism he was often alone in expressing about the company's finances and progress in developing its technology at board meetings. In 2019, Tevanian gave a wide-ranging interview on his time at Theranos for a six-part podcast series called The Dropout, produced by ABC News. In the interview, he said: "I had seen so many things that were bad go on. I would never expect anyone would behave the way that she [Elizabeth Holmes] behaved as a CEO. And believe me, I worked for Steve Jobs. I saw some crazy things. But Elizabeth took it to a new level.”
Risk factors for opioid overdose include opioid dependence, injecting opioids, using high doses of opioids, and use together with alcohol, benzodiazepines, or cocaine. The risk is particularly high following detoxification. Dependence on prescription opioids can occur from their use to treat chronic pain. In young children, an overdose is usually due to opioids that are intended for their parents, older siblings, or grandparents. In mothers who take codeine during breastfeeding, opioid overdoses have occurred in their baby. Codeine is, therefore, not recommended for those who are breastfeeding.
In biochemistry, a cross-linked enzyme aggregate is an immobilized enzyme prepared via cross-linking of the physical enzyme aggregates with a difunctional cross-linker. They can be used as stereoselective industrial biocatalysts.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.